Skip to content

Clinical study for combined chemotherapy with arsenic trioxide for alveolar rhabdomyosarcoma

Clinical study for combined chemotherapy with arsenic trioxide for alveolar rhabdomyosarcoma

Status
Active, not recruiting
Phases
Phase 2
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900024911
Enrollment
Unknown
Registered
2019-08-03
Start date
2019-08-01
Completion date
Unknown
Last updated
2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alveolar rhabdomyosarcoma

Interventions

Sponsors

Sun Yat-Sen Memorial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 14 Years

Inclusion criteria

Inclusion criteria: 1. Untreated alveolar rhabdomyosarcoma patients confirmed by pathology; 2. Patients aged 14 years old and younger; 3. Determined as the middle or high-risk risk group according to Intergroup Rhabdomyosarcoma Study Group (IRSG); 4. Requirements for main organs' functions: normal cardiac function (cardiac ejection fraction >50%); Liver function: alanine aminotransferase <= 5 ULN; bilirubin <=3 ULN; Renal function: creatinine level was normal at the corresponding age; 5. Guardians agreed and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who had suffered from other tumors; 2. Patients who had received chemotherapy or radiation; 3. Patients with one or more critical organs failure such as heart, brain, kidney failure.

Design outcomes

Primary

MeasureTime frame
Objective response rate;

Secondary

MeasureTime frame
Overall survival;Event-free survival;Progression-free survival;Incidence of adverse events;

Countries

China

Contacts

Public ContactYang Li

Sun Yat-Sen Memorial Hospital

drliyang@126.com+86 020-81332045

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026